Table of Contents Author Guidelines Submit a Manuscript
Journal of Oncology
Volume 2011, Article ID 201593, 7 pages
http://dx.doi.org/10.1155/2011/201593
Review Article

Oxaliplatin-Induced Neuropathy in Colorectal Cancer

Division of Medical Oncology, University of Colorado Cancer Center, Aurora, CO 80045, USA

Received 2 September 2011; Accepted 24 October 2011

Academic Editor: Andrea Bonetti

Copyright © 2011 Andrew Weickhardt et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. T. Andre, C. Boni, L. Mounedji-Boudiaf et al., “Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer,” New England Journal of Medicine, vol. 350, no. 23, pp. 2343–2351, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  2. H. J. Schmoll, T. Cartwright, J. Tabernero et al., “Phase III trial of capecitabine plus oxaliplatin as adjuvant therapy for stage III colon cancer: a planned safety analysis in 1,864 patients,” Journal of Clinical Oncology, vol. 25, no. 1, pp. 102–109, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  3. G. Masi, E. Vasile, F. Loupakis et al., “Randomized trial of two induction chemotherapy regimens in metastatic colorectal cancer: an updated analysis,” Journal of the National Cancer Institute, vol. 103, no. 1, pp. 21–30, 2011. View at Publisher · View at Google Scholar · View at PubMed
  4. T. Alcindor and N. Beauger, “Oxaliplatin: a review in the era of molecularly targeted therapy,” Current Oncology, vol. 18, no. 1, pp. 18–25, 2011. View at Google Scholar
  5. S. G. Chaney, E. Raymond, S. Faivre, and J. M. Woynarowski, “Oxaliplatin: mechanism of action and antineoplastic activity,” Seminars in Oncology, vol. 25, no. 2, pp. 4–12, 1998. View at Google Scholar · View at Scopus
  6. J. T. Hartmann and H. P. Lipp, “Toxicity of platinum compounds,” Expert Opinion on Pharmacotherapy, vol. 4, no. 6, pp. 889–901, 2003. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  7. R. J. Cersosimo, “Oxaliplatin-associated neuropathy: a review,” Annals of Pharmacotherapy, vol. 39, no. 1, pp. 128–135, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  8. A. A. Argyriou, P. Polychronopoulos, G. Iconomou, E. Chroni, and H. P. Kalofonos, “A review on oxaliplatin-induced peripheral nerve damage,” Cancer Treatment Reviews, vol. 34, no. 4, pp. 368–377, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  9. H. Adelsberger, S. Quasthoff, J. Grosskreutz, A. Lepier, F. Eckel, and C. Lersch, “The chemotherapeutic oxaliplatin alters voltage-gated Na(+) channel kinetics on rat sensory neurons,” European Journal of Pharmacology, vol. 406, no. 1, pp. 25–32, 2000. View at Publisher · View at Google Scholar · View at Scopus
  10. F. Grolleau, L. Gamelin, M. Boisdron-Celle, B. Lapied, M. Pelhate, and E. Gamelin, “A possible explanation for a neurotoxic effect of the anticancer agent oxaliplatin on neuronal voltage-gated sodium channels,” Journal of Neurophysiology, vol. 85, no. 5, pp. 2293–2297, 2001. View at Google Scholar · View at Scopus
  11. L. Gamelin, O. Capitain, A. Morel et al., “Predictive factors of oxaliplatin neurotoxicity: the involvement of the oxalate outcome pathway,” Clinical Cancer Research, vol. 13, no. 21, pp. 6359–6368, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  12. A. Grothey, “Clinical management of oxaliplatin-associated neurotoxicity,” Clinical Colorectal Cancer, vol. 5, no. 1, supplement 1, pp. S38–S46, 2005. View at Publisher · View at Google Scholar · View at Scopus
  13. Services, U.S.D.o.H.a.H., National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 4.03. 2010.
  14. D. R. Cornblath, V. Chaudhry, K. Carter et al., “Total neuropathy score: validation and reliability study,” Neurology, vol. 53, no. 8, pp. 1660–1664, 1999. View at Google Scholar · View at Scopus
  15. G. Cavaletti, G. Bogliun, L. Marzorati et al., “Grading of chemotherapy-induced peripheral neurotoxicity using the Total Neuropathy Scale,” Neurology, vol. 61, no. 9, pp. 1297–1300, 2003. View at Google Scholar · View at Scopus
  16. J. Cassidy, S. Clarke, E. Díaz-Rubio et al., “Randomized phase III study of capecitabine plus oxaliplatin compared with fluorouracil/folinic acid plus oxaliplatin as first-line therapy for metastatic colorectal cancer,” Journal of Clinical Oncology, vol. 26, no. 12, pp. 2006–2012, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  17. A. Falcone, S. Ricci, I. Brunetti et al., “Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the gruppo oncologico nord ovest,” Journal of Clinical Oncology, vol. 25, no. 13, pp. 1670–1676, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  18. A. Grothey, D. A. Nikcevich, J. A. Sloan et al., “Intravenous calcium and magnesium for oxaliplatin-induced sensory neurotoxicity in adjuvant colon cancer: NCCTG N04C7,” Journal of Clinical Oncology, vol. 29, no. 4, pp. 421–427, 2011. View at Publisher · View at Google Scholar · View at PubMed
  19. C. J. Allegra, G. Yothers, M. J. O'Connell et al., “Initial safety report of NSABP C-08: a randomized phase III study of modified FOLFOX6 with or without bevacizumab for the adjuvant treatment of patients with stage II or III colon cancer,” Journal of Clinical Oncology, vol. 27, no. 20, pp. 3385–3390, 2009. View at Publisher · View at Google Scholar · View at PubMed
  20. A. De Gramont, A. Figer, M. Seymour et al., “Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer,” Journal of Clinical Oncology, vol. 18, no. 16, pp. 2938–2947, 2000. View at Google Scholar
  21. S. R. Land, J. A. Kopec, R. S. Cecchini et al., “Neurotoxicity from oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: NSABP C-07,” Journal of Clinical Oncology, vol. 25, no. 16, pp. 2205–2211, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  22. A. A. Argyriou, P. Polychronopoulos, G. Iconomou et al., “Incidence and characteristics of peripheral neuropathy during oxaliplatin-based chemotherapy for metastatic colon cancer,” Acta Oncologica, vol. 46, no. 8, pp. 1131–1137, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  23. S. B. Park, C. S.Y. Lin, A. V. Krishnan, D. Goldstein, M. L. Friedlander, and M. C. Kiernan, “Long-term neuropathy after oxaliplatin treatment: challenging the dictum of reversibility,” Oncologist, vol. 16, no. 5, pp. 708–716, 2011. View at Publisher · View at Google Scholar · View at PubMed
  24. R. K. Ramanathan, M. L. Rothenberg, A. de Gramont et al., “Incidence and evolution of oxaliplatin-induced eripheral sensory neuropathy in diabetic patients with colorectal cancer: a pooled analysis of three phase III studies,” Annals of Oncology, vol. 21, no. 4, pp. 754–758, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  25. R. M. Goldberg, I. Tabah-Fisch, H. Bleiberg et al., “Pooled analysis of safety and efficacy of oxaliplatin plus fluorouracil/leucovorin administered bimonthly in elderly patients with colorectal cancer,” Journal of Clinical Oncology, vol. 24, no. 25, pp. 4085–4091, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  26. V. Adler, Z. Yin, S. Y. Fuchs et al., “Regulation of JNK signaling by GSTp,” EMBO Journal, vol. 18, no. 5, pp. 1321–1334, 1999. View at Google Scholar · View at Scopus
  27. R. Elsby, N. R. Kitteringham, C. E. Goldring et al., “Increased constitutive c-Jun N-terminal kinase signaling in mice lacking glutathione S-transferase Pi,” Journal of Biological Chemistry, vol. 278, no. 25, pp. 22243–22249, 2003. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  28. C. J. Henderson, A. W. McLaren, G. J. Moffat, E. J. Bacon, and C. R. Wolf, “Pi-class glutathione S-transferase: regulation and function,” Chemico-Biological Interactions, vol. 111-112, pp. 69–82, 1998. View at Publisher · View at Google Scholar · View at Scopus
  29. T. Lecomte, B. Landi, P. Beaune, P. Laurent-Puig, and M. A. Loriot, “Glutathione S-transferase P1 polymorphism (Ile105Val) predicts cumulative neuropathy in patients receiving oxaliplatin-based chemotherapy,” Clinical Cancer Research, vol. 12, no. 10, pp. 3050–3056, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  30. M. Kanai, A. Yoshioka, S. Tanaka et al., “Associations between glutathione S-transferase π Ile105Val and glyoxylate aminotransferase Pro11Leu and Ile340Met polymorphisms and early-onset oxaliplatin-induced neuropathy,” Cancer Epidemiology, vol. 34, no. 2, pp. 189–193, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  31. A. G. Antonacopoulou, A. A. Argyriou, C. D. Scopa et al., “Integrin beta-3 L33P: a new insight into the pathogenesis of chronic oxaliplatin-induced peripheral neuropathy?” European Journal of Neurology, vol. 17, no. 7, pp. 963–968, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  32. S. Lee, H. Won, E. Son et al., “Genetic polymorphism associated with chronic neurotoxicity and recurrence in curatively-resected colon cancer patients receiving oxaliplatin-based adjuvant chemotherapy,” Journal of Clinical Oncology, vol. 28, no. 15, supplement, p. 3583, ASCO Meeting Abstracts, 2010.
  33. C. Tournigand, A. Cervantes, A. Figer et al., “OPTIMOX1: a randomized study of FOLFOX4 or FOLFOX7 with oxaliplatin in a stop-and-go fashion in advanced colorectal cancer—a GERCOR study,” Journal of Clinical Oncology, vol. 24, no. 3, pp. 394–400, 2006. View at Publisher · View at Google Scholar · View at PubMed
  34. H. S. Hochster, A. Grothey, and B. H. Childs, “Use of calcium and magnesium salts to reduce oxaliplatin-related neurotoxicity,” Journal of Clinical Oncology, vol. 25, no. 25, pp. 4028–4029, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  35. A. Grothey, L. L. Hart, K. M. Rowland et al., “Intermittent oxaliplatin (oxali) administration and time-to-treatment-failure (TTF) in metastatic colorectal cancer (mCRC): final results of the phase III CONcePT trial,” Journal of Clinical Oncology, vol. 26, no. 15, supplement, p. 4010, ASCO Meeting Abstracts, 2008.
  36. I. Chau and D. Cunningham, “Treatment in advanced colorectal cancer: what, when and how?” British Journal of Cancer, vol. 100, no. 11, pp. 1704–1719, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  37. B. Chibaudel, F. Maindrault-Goebel, G. Lledo et al., “Can chemotherapy be discontinued in unresectable metastatic colorectal cancer? The GERCOR OPTIMOX2 study,” Journal of Clinical Oncology, vol. 27, no. 34, pp. 5727–5733, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  38. J. Tabernero, E. Aranda, A. Gomez et al., “Phase III study of first-line XELOX plus bevacizumab (BEV) for 6 cycles followed by XELOX plus BEV or single-agent (s/a) BEV as maintenance therapy in patients (pts) with metastatic colorectal cancer (mCRC): the MACRO trial (Spanish Cooperative Group for the Treatment of Digestive Tumors [TTD]),” Journal of Clinical Oncology, vol. 28, no. 15, supplement, p. 3501, ASCO Meeting Abstracts, 2010.
  39. E. Gamelin, L. Gamelin, L. Bossi, and S. Quasthoff, “Clinical aspects and molecular basis of oxaliplatin neurotoxicity: current management and development of preventive measures,” Seminars in Oncology, vol. 29, no. 5, supplement 15, pp. 21–33, 2002. View at Google Scholar
  40. L. Gamelin, M. Boisdron-Celle, R. Delva et al., “Prevention of oxaliplatin-related neurotoxicity by calcium and magnesium infusions: a retrospective study of 161 patients receiving oxaliplatin combined with 5-fluorouracil and leucovorin for advanced colorectal cancer,” Clinical Cancer Research, vol. 10, no. 12, pp. 4055–4061, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  41. N. Knijn, J. Tol, M. Koopman et al., “The effect of prophylactic calcium and magnesium infusions on the incidence of neurotoxicity and clinical outcome of oxaliplatin-based systemic treatment in advanced colorectal cancer patients,” European Journal of Cancer, vol. 47, no. 3, pp. 369–374, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  42. L. Gamelin, M. Boisdron-Celle, A. Morel et al., “Oxaliplatin-related neurotoxicity: interest of calcium-magnesium infusion and no impact on its efficacy,” Journal of Clinical Oncology, vol. 26, no. 7, pp. 1188–1189, 2008. View at Publisher · View at Google Scholar · View at PubMed
  43. S. Cascinu, V. Catalano, L. Cordella et al., “Neuroprotective effect of reduced glutathione on oxaliplatin-based chemotherapy in advanced colorectal cancer: a randomized, double-blind, placebo-controlled trial,” Journal of Clinical Oncology, vol. 20, no. 16, pp. 3478–3483, 2002. View at Publisher · View at Google Scholar
  44. P. C. Lin, M. Y. Lee, W. S. Wang et al., “N-acetylcysteine has neuroprotective effects against oxaliplatin-based adjuvant chemotherapy in colon cancer patients: preliminary data,” Supportive Care in Cancer, vol. 14, no. 5, pp. 484–487, 2006. View at Publisher · View at Google Scholar · View at PubMed
  45. W. S. Wang, J. K. Lin, T. C. Lin et al., “Oral glutamine is effective for preventing oxaliplatin-induced neuropathy in colorectal cancer patients,” Oncologist, vol. 12, no. 3, pp. 312–319, 2007. View at Publisher · View at Google Scholar · View at PubMed
  46. P. Lu, Q. X. Fan, L. X. Wang, X. Wang, H. Zong, and R. L. Wang, “Prophylactic effect of amifostine on oxaliplatin-related neurotoxicity in patients with digestive tract tumors,” Ai Zheng, vol. 27, no. 10, pp. 1117–1120, 2008. View at Google Scholar
  47. Y. Guo, J. L. Palmer, A. Forman et al., “A randomized, double-blinded, placebo-controlled trial of oral alpha lipoic acid to prevent platinum-induced polyneuropathy,” Journal of Clinical Oncology, vol. 29, no. 15, supplement, p. 9010, ASCO Meeting Abstracts, 2011.
  48. S. von Delius, F. Eckel, S. Wagenpfeil et al., “Carbamazepine for prevention of oxaliplatin-related neurotoxicity in patients with advanced colorectal cancer: final results of a randomised, controlled, multicenter phase II study,” Investigational New Drugs, vol. 25, no. 2, pp. 173–180, 2007. View at Publisher · View at Google Scholar · View at PubMed
  49. A. A. Argyriou, E. Chroni, P. Polychronopoulos et al., “Efficacy of oxcarbazepine for prophylaxis against cumulative oxaliplatin-induced neuropathy,” Neurology, vol. 67, no. 12, pp. 2253–2255, 2006. View at Publisher · View at Google Scholar · View at PubMed
  50. P. L. Mitchell, D. Goldstein, M. Michael et al., “Addition of gabapentin to a modified FOLFOX regimen does not reduce oxaliplatin-induced neurotoxicity,” Clinical Colorectal Cancer, vol. 6, no. 2, pp. 146–151, 2006. View at Google Scholar
  51. J. P. Durand, C. Brezault, and F. Goldwasser, “Protection against oxaliplatin acute neurosensory toxicity by venlafaxine,” Anti-Cancer Drugs, vol. 14, no. 6, pp. 423–425, 2003. View at Publisher · View at Google Scholar
  52. R. D. Rao, P. J. Flynn, J. A. Sloan et al., “Efficacy of lamotrigine in the management of chemotherapy-induced peripheral neuropathy: a phase 3 randomized, double-blind, placebo-controlled trial, N01C3,” Cancer, vol. 112, no. 12, pp. 2802–2808, 2008. View at Publisher · View at Google Scholar · View at PubMed
  53. S. B. Park, D. Goldstein, C. S.-Y. Lin, A. V. Krishnan, M. L. Friedlander, and M. C. Kiernan, “Neuroprotection for oxaliplatin-induced neurotoxicity: what happened to objective assessment?” Journal of Clinical Oncology, vol. 29, no. 18, pp. e553–e554, 2011. View at Publisher · View at Google Scholar · View at PubMed
  54. A. Reynolds, C. Laurie, R. Lee Mosley, and H. E. Gendelman, “Oxidative stress and the pathogenesis of neurodegenerative disorders,” International Review of Neurobiology, vol. 82, pp. 297–325, 2007. View at Publisher · View at Google Scholar · View at PubMed
  55. J. Holmes, J. Stanko, M. Varchenko et al., “Comparative neurotoxicity of oxaliplatin, cisplatin, and ormaplatin in a wistar rat model,” Toxicological Sciences, vol. 46, no. 2, pp. 342–351, 1998. View at Publisher · View at Google Scholar · View at PubMed
  56. A. Appert-Collin, F. H. T. Duong, P. Passilly Degrace, J. M. Warter, P. Poindron, and J. P. Gies, “MAPK activation via 5-hydroxytryptamine 1A receptor is involved in the neuroprotective effects of xaliproden,” International Journal of Immunopathology and Pharmacology, vol. 18, no. 1, pp. 21–31, 2005. View at Google Scholar
  57. J. Cassidy, G. A. Bjarnason, T. Hickish et al., “Randomized double blind (DB) placebo (Plcb) controlled phase III study assessing the efficacy of xaliproden (X) in reducing the cumulative peripheral sensory neuropathy (PSN) induced by the oxaliplatin (Ox) and 5-FU/LV combination (FOLFOX4) in first-line treatment of patients (pts) with metastatic colorectal cancer (MCRC),” Journal of Clinical Oncology, vol. 24, no. 18, supplement, p. 3507, 2006. View at Google Scholar
  58. J. P. Durand, G. Deplanque, V. Montheil et al., “Efficacy of venlafaxine for the prevention and relief of oxaliplatin-induced acute neurotoxicity: results of EFFOX, a randomized, double-blind, placebo-controlled phase III trial,” Annals of Oncology. In press.
  59. A. L. Kautio, M. Haanpää, T. Saarto, and E. Kalso, “Amitriptyline in the Treatment of Chemotherapy-Induced Neuropathic Symptoms,” Journal of Pain and Symptom Management, vol. 35, no. 1, pp. 31–39, 2008. View at Publisher · View at Google Scholar · View at PubMed
  60. G. Mariani, O. Garonne, and C. Granetto, “Oxaliplatin induced neuropathy: could gabapentin be the answer?” Journal of Clinical Oncology, vol. 19, no. 19, supplement, p. 2937, ASCO Meeting Abstracts, 2000.
  61. M. W. Saif and S. Hashmi, “Successful amelioration of oxaliplatin-induced hyperexcitability syndrome with the antiepileptic pregabalin in a patient with pancreatic cancer,” Cancer Chemotherapy and Pharmacology, vol. 61, no. 3, pp. 349–354, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus